Eczema Reminder and Accountability Program (ERAP)

• ClinicalTrials.gov Identifier: NCT03735459
• Recruitment Status: Completed
• First Posted: November 8, 2018
• Last Update Posted: August 15, 2019
• Sponsor: McMaster University
• Collaborator: Hamilton Allergy
• Information provided by (Responsible Party): Vince Wu, McMaster University

Study Description

Brief Summary:

Eczema is a chronic disease that requires long term and extensive treatment. However patient adherence to the treatment plans provided to them by their healthcare providers is poor. Frequent follow-up appointments have been demonstrated to improve treatment adherence, this may be due to patients feeling a sense of accountability which motivates them to adhere to their treatment. However, although frequent follow-up appointments are effective, they are not feasible. The goal of the Eczema Reminder and Accountability Program (ERAP) is to assess the effectiveness of a patient reminder system on patient adherence to treatment and the outcome of eczema. Participants will receive weekly/biweekly text messages that encourage them to adhere to their treatment plan, and asks them to assess the severity of their eczema and adherence to treatment for that week using questionnaires. Participants are then asked to send the completed questionnaires to Hamilton Allergy. Should the ERAP improve eczema outcome and treatment adherence, the goal is to use the ERAP as a virtual follow-up to reduce the need for frequent in-office follow-ups.

Condition or disease	Intervention/treatment	Phase
Atopic Dermatitis; Eczema	Behavioral: Patient reminders and accountability questionnaires	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 21 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Impact of an Atopic Dermatitis Education, Reminder, and Accountability Program on Patient Adherence to Treatment and Outcome of Atopic Dermatitis
• Actual Study Start Date: November 13, 2018
• Actual Primary Completion Date: July 1, 2019
• Actual Study Completion Date: July 1, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Patient reminder; Patient Oriented SCORAD (PO-SCORAD): Assess severity of eczema. Adherence Questionnaire (AQ): Assess adherence to eczema treatment plan provided to them by their healthcare provider. Family Dermatology Life Quality Index (FDLQI): Assess impact of the participant's eczema on the family's quality of life. Enrollment: Participants will complete FDLQI and PO-SCORAD. Week 1, 2, and 4: Participants will complete PO-SCORAD and AQ. Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ.	Behavioral: Patient reminders and accountability questionnaires; Participants who are assigned to the patient reminder arm will receive text messages 1, 2, and 4 weeks after enrollment. These text messages will encourage participants to adhere to the provided treatment plan, and ask participants to complete questionnaires to assess their adherence to treatment (in-house Adherence Questionnaire) and severity of eczema (PO-SCORAD) for that week.
No Intervention: No patient reminder/control; Participants in arm 2 are not sent text messages, and will not be asked to complete questionnaires 1, 2, and 4 weeks post enrollment. Participants will be asked to complete questionnaires during enrollment and 6 weeks post enrollment. Enrollment: Participants will complete FDLQI and PO-SCORAD. Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ.

Outcome Measures

Primary Outcome Measures :

1. Change in severity of eczema [ Time Frame: From date of randomization until 6 weeks post randomization. Time frame: 6 weeks. ]

   Participants will complete the Patient Oriented SCORAD (PO-SCORAD) to assess the severity of their eczema. Participants in arm 1 (reminders) will complete the PO-SCORAD on the date of randomization, and weeks 1, 2, 4, and 6 post randomization. Participants in arm 2 (no reminders) will complete the PO-SCORAD on the date of randomization and 6 weeks post randomization.

   To assess the impact of the ERAP on the outcome/severity of eczema, the change between the PO-SCORAD score from randomization and week 6 post randomization will be compared for arm 1 and arm 2.

Secondary Outcome Measures :

1. Treatment adherence [ Time Frame: From 1 week post date of randomization until 6 weeks post date of randomization. Time frame: 5 weeks. ]

   Participants will complete the Adherence Questionnaire (AQ) to assess their adherence to the eczema treatment plan provided.

   Participants in arm 1 (reminders) will complete the AQ on weeks 1, 2, 4, and 6 post randomization.

   Participants in arm 2 (no reminders) will complete the AQ on week 6 post randomization.

   The AQ will be scored for week 6 post randomization and compared between arms 1 and 2 to determine the impact of the ERAP on treatment adherence.

2. Change in family quality of life [ Time Frame: 6 weeks. ]

   To assess the impact of eczema on the family's quality of life, the participants' parents/guardians will be asked to complete the Family Dermatology Life Quality Index (FDLQI).

   Family members of participants in both arms 1 and 2 will be asked to complete the FDLQI on the date of randomization and 6 weeks post randomization.

   The change in FDLQI between the date of randomization and 6 weeks post randomization will be compared between arms 1 and 2 to assess the impact of the ERAP on the family's quality of life.

Eligibility Criteria

• Ages Eligible for Study: up to 16 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Chronic atopic dermatitis.
• Age 0 to 16.

Exclusion Criteria:

-

Contacts and Locations

Locations

Canada, Ontario

Hamilton Allergy

Hamilton, Ontario, Canada, L8S 1G5

Sponsors and Collaborators

McMaster University

Hamilton Allergy

Investigators

• Principal Investigator: Vince Wu; McMaster University

More Information

Publications:

Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, Oranje A, Deleuran M, Cambazard F, Svensson A, Simon D, Benfeldt E, Reunala T, Mazereeuv J, Boralevi F, Kunz B, Misery L, Mortz CG, Darsow U, Gelmetti C, Diepgen T, Ring J, Moehrenschlager M, Gieler U, Taïeb A; PO-SCORAD Investigators Group. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011 Aug;66(8):1114-21. doi: 10.1111/j.1398-9995.2011.02577.x. Epub 2011 Mar 18.

Basra MK, Sue-Ho R, Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol. 2007 Mar;156(3):528-38. Erratum in: Br J Dermatol. 2007 Apr;156(4):791.

Bass AM, Anderson KL, Feldman SR. Interventions to Increase Treatment Adherence in Pediatric Atopic Dermatitis: A Systematic Review. J Clin Med. 2015 Jan 27;4(2):231-42. doi: 10.3390/jcm4020231. Review.

• Responsible Party: Vince Wu, McMaster Co-op Student, McMaster University
• ClinicalTrials.gov Identifier: NCT03735459
• Other Study ID Numbers: ERAP
• First Posted: November 8, 2018
• Last Update Posted: August 15, 2019
• Last Verified: August 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Vince Wu, McMaster University:

Treatment adherence and compliance

Additional relevant MeSH terms:

Dermatitis, Atopic; Dermatitis; Eczema; Skin Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases